- Home
- CRNX vs MIST Comparison
CRNX vs MIST Comparison
Compare CRNX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- MIST
- Stock Information
- Founded
- CRNX 2008
- MIST 2003
- Country
- CRNX United States
- MIST Canada
- Employees
- CRNX N/A
- MIST N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- MIST Health Care
- Exchange
- CRNX Nasdaq
- MIST Nasdaq
- Market Cap
- CRNX 2.8B
- MIST 89.8M
- IPO Year
- CRNX 2018
- MIST N/A
- Fundamental
- Price
- CRNX $29.44
- MIST $1.92
- Analyst Decision
- CRNX Strong Buy
- MIST Strong Buy
- Analyst Count
- CRNX 10
- MIST 2
- Target Price
- CRNX $75.00
- MIST $7.50
- AVG Volume (30 Days)
- CRNX 641.8K
- MIST 581.3K
- Earning Date
- CRNX 08-07-2025
- MIST 08-07-2025
- Dividend Yield
- CRNX N/A
- MIST N/A
- EPS Growth
- CRNX N/A
- MIST N/A
- EPS
- CRNX N/A
- MIST N/A
- Revenue
- CRNX $760,000.00
- MIST N/A
- Revenue This Year
- CRNX $402.12
- MIST N/A
- Revenue Next Year
- CRNX $770.88
- MIST N/A
- P/E Ratio
- CRNX N/A
- MIST N/A
- Revenue Growth
- CRNX N/A
- MIST N/A
- 52 Week Low
- CRNX $24.10
- MIST $0.63
- 52 Week High
- CRNX $62.53
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- CRNX 42.12
- MIST 64.75
- Support Level
- CRNX $28.34
- MIST $1.85
- Resistance Level
- CRNX $30.85
- MIST $1.97
- Average True Range (ATR)
- CRNX 1.10
- MIST 0.10
- MACD
- CRNX -0.24
- MIST 0.00
- Stochastic Oscillator
- CRNX 25.52
- MIST 75.00
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).